<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774930</url>
  </required_header>
  <id_info>
    <org_study_id>2-55-52030-730</org_study_id>
    <secondary_id>TR321</secondary_id>
    <secondary_id>2010-019066-92</secondary_id>
    <nct_id>NCT00774930</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome</brief_title>
  <acronym>ELECT</acronym>
  <official_title>A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine whether monthly deep subcutaneous (s.c.)
      injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling
      diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue
      medication to control symptoms in subjects with carcinoid syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of a Screening period, conducted up to 4 months before randomisation,
      followed by three phases: a 16-week, double blind (DB), randomised, placebo-controlled phase;
      a 32-week initial open label (IOL) phase; and a long term open label extension (LTOLE) phase.

      The DB phase evaluated lanreotide Autogel versus placebo in subjects with a history of
      carcinoid syndrome (flushing and/or diarrhoea). This was followed by a 32-week IOL phase in
      which all subjects received lanreotide Autogel 120 mg every 4 weeks. Subjects in countries
      where lanreotide Autogel had not been approved for the treatment of carcinoid syndrome, who
      were well-controlled at the end of the 32-week IOL phase and chose to continue to receive
      lanreotide Autogel, were given the option of participating in a LTOLE phase. The LTOLE phase
      of the study was planned to end at least 2 years after the last subject had completed his/her
      participation in the 32-week IOL phase or when marketing approval for the treatment of
      symptoms of carcinoid syndrome had been obtained in the respective countries (whichever
      occurred first) or at any time the study was terminated by the Sponsor. The actual overall
      duration of the study was 6.5 years. During the LTOLE phase all subjects continued to be
      treated with lanreotide Autogel 120 mg every 4 weeks.

      The study planned to enrol approximately 100 adult subjects worldwide. Screening continued
      until 115 subjects were enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Days With Subcutaneous Octreotide as Rescue Medication</measure>
    <time_frame>16-week DB phase</time_frame>
    <description>Use of s.c. octreotide required to control symptoms associated with carcinoid syndrome, measured as the percentage of days that s.c. octreotide was used as rescue medication, based on subject Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS) diary records.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.</measure>
    <time_frame>16-week DB phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.</measure>
    <time_frame>16-week DB phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days of Use of Other Rescue Medication</measure>
    <time_frame>16-week DB phase</time_frame>
    <description>Usage of other concomitant rescue medications for diarrhoea and/or flushing events, measured as the percentage of days that the medications were used as rescue medication based on subject IVRS/IWRS diary records. Subjects were required to record the use and dose of s.c. octreotide, if any, as well as the use of other concomitant rescue medications (e.g. loperamide 2 mg tabs, and/or tincture of opium).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study</measure>
    <time_frame>16-week DB phase</time_frame>
    <description>Subjects who rolled over early were those who received less than four DB injections before receiving the first IOL injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in &quot;Global Health Status/Quality of Life (QoL)&quot; Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)</measure>
    <time_frame>Baseline and Week 12 of DB phase</time_frame>
    <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
Q29 and Q30 range from 1 (Very poor) to 7 (Excellent) with 1 being worst case and 7 the most favourable answer. Scores were derived according to the rules contained within the EORTC scoring manual. All of the scores range in score from 0 to 100. A high score for global health status/QoL represents high QoL. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. Raw score = RS = (I1 + I2 +…+ In)/n.
For global health status/QoL: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in &quot;Gastrointestinal (G.I). Symptoms&quot; Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]</measure>
    <time_frame>Baseline and Week 12 of DB phase</time_frame>
    <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n.
For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in QoL in &quot;Endocrine Symptoms&quot; Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)</measure>
    <time_frame>Baseline and Week 12 of DB phase</time_frame>
    <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n.
For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA])</measure>
    <time_frame>Baseline and Week 12 of DB phase</time_frame>
    <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA])</measure>
    <time_frame>Baseline and Week 12 of DB phase</time_frame>
    <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Carcinoid Syndrome</condition>
  <arm_group>
    <arm_group_label>Lanreotide Autogel (Somatuline Depot) 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).
After completing the DB phase (or if they met criteria for early roll over [ERO]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).
After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first]).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <description>deep s.c. injection, 120 mg, every 4 weeks (±3 days).</description>
    <arm_group_label>Lanreotide Autogel (Somatuline Depot) 120 mg</arm_group_label>
    <other_name>Somatuline</other_name>
    <other_name>Somatuline Depot</other_name>
    <other_name>Somatuline Autogel</other_name>
    <other_name>Lanreotide Autogel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).</description>
    <arm_group_label>Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects were eligible for participation in the study if they met the following criteria:

          1. At least 18 years of age at the time of first dosing.

          2. Subjects must have given signed informed consent before any study related activities
             were conducted.

          3. Subjects in the United States of America (USA) must have given written authorisation
             for the release of protected health information in compliance with the Health
             Insurance Portability and Accountability Act (HIPAA) regulations; subjects in other
             countries must have provided appropriate authorisation as needed by regulatory
             authorities in each country.

          4. Subjects must have been willing to receive s.c. octreotide injections as rescue
             medication, as needed to control their symptoms, if any.

          5. If female, the subject must not have been pregnant (confirmed by negative pregnancy
             test) and must have had the following documented via verbally given history:

               -  At least 1 year postmenopausal (natural cessation of menses), or

               -  Surgically sterile (if by tubal ligation, surgery must have been performed more
                  than 3 months prior to entry into the study), or

               -  If the subject was of childbearing potential and sexually active, she must have
                  been using an acceptable form of contraception (oral, injected, transdermal or
                  implanted contraceptives, diaphragm or barrier method with spermicidal and/or
                  intrauterine device); local methods such as condoms or sponges/vaginal tablets
                  were not acceptable forms of contraception.

          6. Subjects with a histopathologically confirmed diagnosis of carcinoid tumour or, a
             carcinoid tumour of unknown location with liver metastases (documented biopsy), and a
             history of carcinoid syndrome (flushing and/or diarrhoea) who were either naïve to
             treatment with a somatostatin analogue (SSTa) or responsive (according to the opinion
             of the principal investigator) to conventional doses of Sandostatin LAR® Depot (LAR;
             ≤30 mg every 4 weeks) or to daily doses of ≤600 μg of s.c. octreotide.

          7. Confirmation of positive somatostatin receptor (SSTR) status by somatostatin receptor
             scintigraphy (SRS; up to 6 months prior to study entry at the Screening Visit).

          8. Absence of tumour progression documented by two sequential computed tomography (CT)
             scans or two sequential magnetic resonance imaging (MRI) scans (≥3 months apart); the
             last CT or MRI scan must have been performed within 6 months of study entry (Screening
             Visit).

          9. Subjects previously treated with LAR, must have received their last dose of LAR at
             least 4 weeks prior to first dose of study treatment (no later than at the Screening
             Visit).

         10. Be able to communicate and cooperate with the principal investigator and the staff and
             willing to comply with the study instructions.

        Subjects were excluded from entering the study for the following reasons:

          1. History of known allergy or hypersensitivity to investigational drug or any components
             of its formulation, or octreotide.

          2. History of carcinoid syndrome refractory to treatment with conventional doses of SSTa.

          3. Treatment with any other investigational drug within 30 days prior to study entry
             (Screening Visit) and/or at any time during the subject's participation in the study.

          4. Treatment with interferon, chemotherapy and/or radiotherapy (a radiolabelled SSTa)
             and/or tumour debulking &lt;3 months prior to study entry (Screening Visit).

          5. History of hepatic arterial embolisation, hepatic arterial chemoembolisation and/or
             selective internal radiation therapy (selective internal radiation [SIR] therapy
             [SIRT]; e.g. SIR Spheres) &lt;6 months prior to study entry (Screening Visit).

          6. Short bowel syndrome.

          7. Uncontrolled diabetes and/or hypertension.

          8. Severe renal impairment (glomerular filtration rate &lt;30 mL/min/1.73 m2) and/or severe
             liver impairment as evidenced by serum total bilirubin &gt;1.5 mg/dL associated with bile
             duct blockage or with alkaline phosphatase (ALP), aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) &gt;5.0 upper limit of normal (ULN).

          9. Diagnosis of cardiac disease New York Heart Association (NYHA) functional
             classification &gt;Class I. (Subject has limitation of physical activity. Ordinary
             physical activity causes undue fatigue, palpitation, or dyspnoea).

         10. Life expectancy less than 1 year.

         11. Any malignancies except carcinoid tumour, basocellular carcinoma of the skin, in situ
             carcinoma of the cervix and ≥5 years disease free after curative cancer treatment.

         12. Any serious medical condition that could jeopardise the safety of the subject and/or
             the efficacy assessments of the study.

         13. Subject is being treated with a proton pump inhibitor (PPI) and has been at a stable
             dose (no change in dose or frequency of administration) for less than 4 weeks at study
             entry (Screening Visit).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edda Gomez-Panzani, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles Health Care System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Outpatient Cancer Center</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Science Center</name>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <zip>70065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Care Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Liver Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biocancer - Centro de Pesquisa e Tratamento do Câncer</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital LifeCenter</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxion Medicina Oncológica</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário de Brasilia</name>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de São José do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VFN Onkologicka klinika</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Gangaram Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indo-American Cancer Institute &amp; Research Centre</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santokaba Durlabhji Memorial Hospital and Research Institute</name>
      <address>
        <city>Jaipur</city>
        <zip>302015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer cancer hospital and research centre</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Super Speciality hospital</name>
      <address>
        <city>Nasik</city>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Endokrynologii, Diabetologii i Leczenia Izotopami</name>
      <address>
        <city>Wrocław</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-Federal Institution of Healthcare &quot;Central Clinical Hospital # 1 of the LLC &quot;Russian Railways (RZD)&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Academy of Medical Sciences &quot;Russian Oncological Research Centre named after N.N. Blokhin RAMS&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Institution of Healthcare &quot;Leningradsky Regional Oncological Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Endocrinology, diabetes and metabolic diseases, Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Vojvodina, Sremska Kamenica</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21 204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rondebosch Oncology Unit</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westridge Medical Centre</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GVI Oncology Clinical Trial Unit</name>
      <address>
        <city>Western Cape</city>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes University Medical Faculty</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Oncology Dispensary</name>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernivtsi Regional Oncology Center</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Medical Radiology Chair of Dnepropetrovsk State Medical Academy</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Anticancer Center, Department of oncoproctology</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital #2, Proctology department</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Oncological Hospital, Thoracic department</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre &quot;Mriya&quot;</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Clinical Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorods'ka Tsentral'na Mis'ka Klinichna Likarnya, Mis'kyy Onkologichnyy Tsentr</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya Regional Clinical Oncological Center, Vinnytsya State Medical University</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
  </removed_countries>
  <results_reference>
    <citation>Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; ELECT Study Group *. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Endocr Pract. 2016 Sep;22(9):1068-80. doi: 10.4158/EP151172.OR. Epub 2016 May 23.</citation>
    <PMID>27214300</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <results_first_submitted>August 5, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2016</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoid tumor</keyword>
  <keyword>Somatuline Depot</keyword>
  <keyword>Lanreotide Autogel</keyword>
  <keyword>Neuroendocrine tumor</keyword>
  <keyword>NET</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Flushing</keyword>
  <keyword>Carcinoid tumour</keyword>
  <keyword>Neuroendocrine tumour</keyword>
  <keyword>Diarrhoea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from multiple sites across countries from May 2009. The study was completed in December 2015.</recruitment_details>
      <pre_assignment_details>A total of 153 subjects were screened; 115 were randomized and 38 failed screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
          <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the initial open label (IOL) phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the long term open label extension (LTOLE) phase.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>DB Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59">One subject was randomised to receive lanreotide Autogel, but erroneously received placebo.</participants>
                <participants group_id="P2" count="56">One subject was randomised to receive lanreotide Autogel, but erroneously received placebo.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45">Received 4 DB study injections AND continued to IOL phase OR</participants>
                <participants group_id="P2" count="34">had diary data at least up to day 21 after 4th dose, regardless of missing diary data before day 21.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Roll Over (ERO) to IOL phase</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started Nonprotocol Radiation therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>IOL Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="46">Includes 1 subject listed as completing and withdrawing from the DB phase due to brain radiation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Consumed Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Peptide Receptor Radionuclide Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Brain radiation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>LTOLE Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">24 subjects from IOL did not enter LTOLE (11 completed IOL, 13 did not complete IOL).</participants>
                <participants group_id="P2" count="25">20 subjects from IOL did not enter LTOLE (12 completed IOL, 8 did not complete IOL).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tumour Progression of Hepatic Metastases</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Proton Pump Inhibitor Dose Adjusted</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
          <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase. Intent-to-treat (ITT) population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="10.6"/>
                    <measurement group_id="B2" value="59.3" spread="11.6"/>
                    <measurement group_id="B3" value="58.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days With Subcutaneous Octreotide as Rescue Medication</title>
        <description>Use of s.c. octreotide required to control symptoms associated with carcinoid syndrome, measured as the percentage of days that s.c. octreotide was used as rescue medication, based on subject Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS) diary records.</description>
        <time_frame>16-week DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Subcutaneous Octreotide as Rescue Medication</title>
          <description>Use of s.c. octreotide required to control symptoms associated with carcinoid syndrome, measured as the percentage of days that s.c. octreotide was used as rescue medication, based on subject Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS) diary records.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
          <units>Percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.72" lower_limit="25.02" upper_limit="42.42"/>
                    <measurement group_id="O2" value="48.49" lower_limit="39.57" upper_limit="57.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0165</p_value>
            <method>ANCOVA</method>
            <method_desc>This analysis does not include any imputation for the early roll over subjects</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.</title>
        <time_frame>16-week DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.</title>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
          <units>Number of events per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.83"/>
                    <measurement group_id="O2" value="1.35" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2544</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA included treatment group and 2 stratification variables at randomisation as factors and average frequency of diarrhoea per day during Screening</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.</title>
        <time_frame>16-week DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.</title>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
          <units>Number of events per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="1.45"/>
                    <measurement group_id="O2" value="1.75" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days of Use of Other Rescue Medication</title>
        <description>Usage of other concomitant rescue medications for diarrhoea and/or flushing events, measured as the percentage of days that the medications were used as rescue medication based on subject IVRS/IWRS diary records. Subjects were required to record the use and dose of s.c. octreotide, if any, as well as the use of other concomitant rescue medications (e.g. loperamide 2 mg tabs, and/or tincture of opium).</description>
        <time_frame>16-week DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days of Use of Other Rescue Medication</title>
          <description>Usage of other concomitant rescue medications for diarrhoea and/or flushing events, measured as the percentage of days that the medications were used as rescue medication based on subject IVRS/IWRS diary records. Subjects were required to record the use and dose of s.c. octreotide, if any, as well as the use of other concomitant rescue medications (e.g. loperamide 2 mg tabs, and/or tincture of opium).</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" spread="19.34"/>
                    <measurement group_id="O2" value="6.25" spread="17.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study</title>
        <description>Subjects who rolled over early were those who received less than four DB injections before receiving the first IOL injection.</description>
        <time_frame>16-week DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study</title>
          <description>Subjects who rolled over early were those who received less than four DB injections before receiving the first IOL injection.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in &quot;Global Health Status/Quality of Life (QoL)&quot; Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)</title>
        <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
Q29 and Q30 range from 1 (Very poor) to 7 (Excellent) with 1 being worst case and 7 the most favourable answer. Scores were derived according to the rules contained within the EORTC scoring manual. All of the scores range in score from 0 to 100. A high score for global health status/QoL represents high QoL. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. Raw score = RS = (I1 + I2 +…+ In)/n.
For global health status/QoL: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
        <time_frame>Baseline and Week 12 of DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in &quot;Global Health Status/Quality of Life (QoL)&quot; Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)</title>
          <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
Q29 and Q30 range from 1 (Very poor) to 7 (Excellent) with 1 being worst case and 7 the most favourable answer. Scores were derived according to the rules contained within the EORTC scoring manual. All of the scores range in score from 0 to 100. A high score for global health status/QoL represents high QoL. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. Raw score = RS = (I1 + I2 +…+ In)/n.
For global health status/QoL: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="14.18"/>
                    <measurement group_id="O2" value="-1.72" spread="18.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in “Gastrointestinal (G.I). Symptoms” Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]</title>
        <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n.
For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
        <time_frame>Baseline and Week 12 of DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in “Gastrointestinal (G.I). Symptoms” Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]</title>
          <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n.
For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.06" spread="12.80"/>
                    <measurement group_id="O2" value="0.10" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in QoL in “Endocrine Symptoms” Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)</title>
        <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n.
For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
        <time_frame>Baseline and Week 12 of DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in QoL in “Endocrine Symptoms” Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)</title>
          <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.
The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n.
For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.83" spread="18.98"/>
                    <measurement group_id="O2" value="-2.69" spread="22.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA])</title>
        <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.</description>
        <time_frame>Baseline and Week 12 of DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA])</title>
          <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
          <units>μg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1125.8" spread="12579.4"/>
                    <measurement group_id="O2" value="801.5" spread="2294.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA])</title>
        <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.</description>
        <time_frame>Baseline and Week 12 of DB phase</time_frame>
        <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanreotide Autogel (Somatuline Depot) 120 mg</title>
            <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA])</title>
          <description>Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.</description>
          <population>ITT population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group); n=number of subjects taken into account for the analysis. Only the observed data are used in the calculation. The missing data are excluded from the analysis.</population>
          <units>μmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-201.4" spread="1009.9"/>
                    <measurement group_id="O2" value="36.3" spread="142.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from the time the subject signed informed consent to the exit visit (up to 16 weeks of DB phase, 32 weeks of IOL phase and every 4 subsequent weeks in the LTOLE phase until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first]).</time_frame>
      <desc>Safety population: All randomised subjects who received at least 1 injection of study treatment; subjects were analysed under the actual treatment received. For placebo group (DB phase) n=57 as 1 subject was randomised to lanreotide Autogel but erroneously received placebo.
Treatment-emergent AEs (TEAEs) reported in the IOL or LTOLE phases are AEs that were either not present or were of moderate or severe intensity prior to the first dose of lanreotide Autogel during that phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lanreotide Autogel (Somatuline Depot) 120 mg (DB Phase)</title>
          <description>Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (DB Phase)</title>
          <description>Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase.</description>
        </group>
        <group group_id="E3">
          <title>Lanreotide Autogel (Somatuline Depot) 120 mg (IOL Phase)</title>
          <description>All 101 subjects in the IOL phase received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks (56 and 45 of these subjects received treatment with lanreotide Autogel and placebo, respectively, during the DB phase).</description>
        </group>
        <group group_id="E4">
          <title>Lanreotide Autogel (Somatuline Depot) 120 mg (LTOLE Phase)</title>
          <description>All 57 subjects in the LTOLE phase received further deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (32 and 25 of these subjects received treatment with lanreotide Autogel and placebo, respectively, during the DB phase).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness permanent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E4" events="25" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E4" events="14" subjects_affected="9" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>With permission from the Sponsor, each investigator may have published or reported data from their own subjects. The study data in aggregate are the property of the Sponsor and may not be published without permission of the Sponsor. The Sponsor is the final arbitrator of issues relating to the publication or presentation of the aggregate data.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None specified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director, Oncology</name_or_title>
      <organization>Ipsen</organization>
      <phone>clinical.trials@ipsen.com</phone>
      <email>clinical.trials@ipsen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

